Mozobil Associated With An Increased Risk Of Secondary Cancer The Myeloma Beacon A new study indicates that patients treated with Mozobil prior to a stem cell transplant may have an increased risk of developing a secondary cancer. The patients in the new study were being treated for either lymphoma or myeloma. They were given ... |
